D
Overview
Datazymes builds data-driven platforms and applications for the pharmaceutical industry, integrating, managing, and securing data. It adds interactive analytics apps that enable machine-driven, human-assisted analysis without requiring advanced querying or coding. Its approach combines a flexible, pharma-focused data platform with ready-to-use analytics apps, avoiding rigid software or long consulting cycles. The goal is to help pharma teams turn data into actionable insights quickly and easily through accessible tools.
Work here?Claim your company
Simplify's take
What believers are saying
- September 12, 2026 homepage spotlights commercial analytics and automation after the Celero deal.
- LinkedIn showed 51-200 employees on September 19, 2026, with hiring still active.
- Celero brings U.S. pharma clients, creating immediate cross-sell opportunities for DataZymes.
What critics are saying
- Tracxn says DataZymes has not raised funding, increasing reliance on customer revenue.
- Celero integration on August 15, 2026 risks client churn, team loss, and IP overlap.
- Failure against Salesforce and Veeva traps DataZymes in a narrow, dead-end niche.
What makes Datazymes unique
- August 15, 2026 acquisition of Celero adds SeeData Suite CRM and call planning.
- DataZymes spans Philadelphia, Bengaluru, and Noida, bridging U.S. pharma and India delivery.
- Its pharma-grade analytics focus targets small- to mid-sized pharmaceutical commercial operations.
Help us improve and share your feedback! Did you find this helpful?